These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19721069)

  • 21. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
    Naito T; Izumi K; Kodama E; Sakagami Y; Kajiwara K; Nishikawa H; Watanabe K; Sarafianos SG; Oishi S; Fujii N; Matsuoka M
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1013-8. PubMed ID: 19114674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.
    Sonza S; Johnson A; Tyssen D; Spelman T; Lewis GR; Paull JR; Tachedjian G
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3565-8. PubMed ID: 19528284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():3-7. PubMed ID: 15742549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
    Chong H; Qiu Z; Su Y; He Y
    J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.
    Chang CH; Hinkula J; Loo M; Falkeborn T; Li R; Cardillo TM; Rossi EA; Goldenberg DM; Wahren B
    PLoS One; 2012; 7(7):e41235. PubMed ID: 22844444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
    Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
    Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
    [No Abstract]   [Full Text] [Related]  

  • 27. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A RhoA-derived peptide inhibits human immunodeficiency virus-1 entry in vitro.
    Maselko M; Ward C; Pastey M
    Curr HIV Res; 2011 Jan; 9(1):1-5. PubMed ID: 21198428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional epitope analysis of the human CD11a/CD18 molecule (LFA-1, lymphocyte function-associated antigen 1) involved in HIV-1-induced syncytium formation.
    Vermot-Desroches C; Rigal D; Escaich S; Bernaud J; Pichoud C; Lamelin JP; Trepo C
    Scand J Immunol; 1991 Oct; 34(4):461-70. PubMed ID: 1718027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
    Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
    J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.
    Ashkenazi A; Wexler-Cohen Y; Shai Y
    Biochim Biophys Acta; 2011 Oct; 1808(10):2352-8. PubMed ID: 21762676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
    Lu J; Sista P; Giguel F; Greenberg M; Kuritzkes DR
    J Virol; 2004 May; 78(9):4628-37. PubMed ID: 15078945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
    Fung HB; Guo Y
    Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.
    Wang Q; Bi W; Zhu X; Li H; Qi Q; Yu F; Lu L; Jiang S
    J Virol; 2015 Jul; 89(13):6960-4. PubMed ID: 25903343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.
    Heredia A; Gilliam B; DeVico A; Le N; Bamba D; Flinko R; Lewis G; Gallo RC; Redfield RR
    AIDS; 2007 Jun; 21(10):1317-22. PubMed ID: 17545708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.